bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. Robert W. Baird reduced their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. Bank of America dropped their price target on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Barclays decreased their price target on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. lowered bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, bluebird bio currently has an average rating of “Hold” and an average target price of $4.63.

bluebird bio Price Performance

Shares of bluebird bio stock opened at $0.47 on Friday. The stock has a market capitalization of $90.36 million, a P/E ratio of -0.21 and a beta of 0.75. bluebird bio has a 12 month low of $0.45 and a 12 month high of $5.53. The business has a 50 day simple moving average of $0.53 and a two-hundred day simple moving average of $0.83. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The company had revenue of $18.57 million during the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. As a group, analysts predict that bluebird bio will post -1.41 EPS for the current fiscal year.

Institutional Trading of bluebird bio

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares during the period. AQR Capital Management LLC boosted its stake in bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares in the last quarter. Allegheny Financial Group LTD bought a new position in shares of bluebird bio during the 2nd quarter valued at $25,000. Rhumbline Advisers increased its holdings in shares of bluebird bio by 25.4% in the second quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock worth $288,000 after buying an additional 59,219 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in bluebird bio by 19.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock worth $675,000 after acquiring an additional 111,574 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.